Page last updated: 2024-11-03

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Choroid Neovascularization

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Choroid Neovascularization in 2 studies

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Li, L1
Liu, J1
Xu, A1
Heiduschka, P1
Eter, N1
Chen, C1
Birke, K1
Lipo, E1
Birke, MT1
Kumar-Singh, R1

Other Studies

2 other studies available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Choroid Neovascularization

ArticleYear
Expression of purinergic receptors on microglia in the animal model of choroidal neovascularisation.
    Scientific reports, 2021, 06-11, Volume: 11, Issue:1

    Topics: Animals; Choroidal Neovascularization; Lasers; Mice; Microglia; Purinergic P2 Receptor Antagonists;

2021
Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Administration, Topical; Animals; Choroidal Neovascularization; Complement Activation; Complement Me

2013